241 related articles for article (PubMed ID: 18533893)
1. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
Wu L; Huang TG; Meseck M; Altomonte J; Ebert O; Shinozaki K; García-Sastre A; Fallon J; Mandeli J; Woo SL
Hum Gene Ther; 2008 Jun; 19(6):635-47. PubMed ID: 18533893
[TBL] [Abstract][Full Text] [Related]
2. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
Altomonte J; Wu L; Chen L; Meseck M; Ebert O; García-Sastre A; Fallon J; Woo SL
Mol Ther; 2008 Jan; 16(1):146-53. PubMed ID: 18071337
[TBL] [Abstract][Full Text] [Related]
3. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
4. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.
Altomonte J; Wu L; Meseck M; Chen L; Ebert O; Garcia-Sastre A; Fallon J; Mandeli J; Woo SL
Cancer Gene Ther; 2009 Mar; 16(3):266-78. PubMed ID: 18846115
[TBL] [Abstract][Full Text] [Related]
5. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
Shinozaki K; Ebert O; Kournioti C; Tai YS; Woo SL
Mol Ther; 2004 Mar; 9(3):368-76. PubMed ID: 15006603
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.
Altomonte J; Braren R; Schulz S; Marozin S; Rummeny EJ; Schmid RM; Ebert O
Hepatology; 2008 Dec; 48(6):1864-73. PubMed ID: 19003878
[TBL] [Abstract][Full Text] [Related]
7. The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer.
Yamaki M; Shinozaki K; Sakaguchi T; Meseck M; Ebert O; Ohdan H; Woo SL
Int J Mol Med; 2013 Feb; 31(2):299-306. PubMed ID: 23232984
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
[TBL] [Abstract][Full Text] [Related]
10. Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.
Altomonte J; Marozin S; De Toni EN; Rizzani A; Esposito I; Steiger K; Feuchtinger A; Hellerbrand C; Schmid RM; Ebert O
Mol Ther; 2013 Nov; 21(11):2032-42. PubMed ID: 23939023
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
[TBL] [Abstract][Full Text] [Related]
12. Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment.
Ausubel LJ; Meseck M; Derecho I; Lopez P; Knoblauch C; McMahon R; Anderson J; Dunphy N; Quezada V; Khan R; Huang P; Dang W; Luo M; Hsu D; Woo SL; Couture L
Hum Gene Ther; 2011 Apr; 22(4):489-97. PubMed ID: 21083425
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
14. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
15. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
16. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
[TBL] [Abstract][Full Text] [Related]
17. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
18. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
19. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
20. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
